Drugs / ALT-P7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03281824 | Jan 2018 → Mar 2020 | HER2 positive breast carcinoma | Alteogen, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-10 | Alteogen, Inc. | Results 알테오젠, World ADC서 ADC 개발 패러다임 바꿀 ALT-B4 경쟁력 공개 alteogen.com ↗
실험 결과, ALT-B4 병용 SC 투여군에서는 투약 후 빠른 흡수 속도를 보이며 ALT-B4 미사용군과 비교해 전신 약물 노출(systemic exposure)과 생체이용률(bioavailability)이 향상된 데이터가 도출됐다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-10 | Alteogen, Inc. | 알테오젠, World ADC서 ADC 개발 패러다임 바꿀 ALT-B4 경쟁력 공개 alteogen.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALT-P7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03281824 ↗ |
| Known as | HM2-MMAE | “ALT-P7 (HM2-MMAE)” NCT03281824 ↗ |
| Modality | Other / unclassified | “Antibody-Drug Conjugate” NCT03281824 ↗ |
| Route | Intravenous | “Patients received ALT-P7(0.3 mg/kg\~5.4 mg/kg, 7 groups) intravenously on Day 1 of each 3-week cycle” NCT03281824 ↗ |